This company listing is no longer active
Plant-Based Investment Past Earnings Performance
Past criteria checks 0/6
Plant-Based Investment's earnings have been declining at an average annual rate of -55.3%, while the Pharmaceuticals industry saw earnings growing at 29.8% annually. Revenues have been declining at an average rate of 23.6% per year.
Key information
-55.3%
Earnings growth rate
-50.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -23.6% |
| Return on equity | -184.5% |
| Net Margin | 140.2% |
| Last Earnings Update | 31 Jul 2022 |
Revenue & Expenses Breakdown
How Plant-Based Investment makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 22 | -16 | -23 | 3 | 0 |
| 30 Apr 22 | -22 | -28 | 3 | 0 |
| 31 Jan 22 | -15 | -21 | 4 | 0 |
| 31 Oct 21 | -1 | -8 | 4 | 0 |
| 31 Jul 21 | 5 | 1 | 3 | 0 |
| 30 Apr 21 | 16 | 14 | 2 | 0 |
| 31 Jan 21 | 3 | 0 | 2 | 0 |
| 31 Oct 20 | -13 | -15 | 2 | 0 |
| 31 Jul 20 | -15 | -17 | 2 | 0 |
| 30 Apr 20 | -30 | -31 | 2 | 0 |
| 31 Jan 20 | -11 | -12 | 2 | 0 |
| 31 Oct 19 | -1 | -3 | 2 | 0 |
| 31 Jul 19 | 10 | 9 | 2 | 0 |
| 30 Apr 19 | 25 | 22 | 2 | 0 |
| 31 Jan 19 | 13 | 12 | 2 | 0 |
| 31 Oct 18 | 6 | 3 | 3 | 0 |
Quality Earnings: PBIC is currently unprofitable.
Growing Profit Margin: PBIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBIC is unprofitable, and losses have increased over the past 5 years at a rate of 55.3% per year.
Accelerating Growth: Unable to compare PBIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.5%).
Return on Equity
High ROE: PBIC has a negative Return on Equity (-184.54%), as it is currently unprofitable.